Live tape
Top 8, mentions 7d28,456NVDA13,491 mentions▲ +0.04ANT4,066 mentions▲ +0.07GOOGL2,885 mentions▲ +0.04SPY2,240 mentions▲ +0.05QQQ1,768 mentions▲ +0.03SPCX1,536 mentions▲ +0.07AMD1,330 mentions▲ +0.06AAPL1,140 mentions▲ +0.04

Equity · Healthcare

RLMD

NASDAQ

Relmada Therapeutics (RLMD)

5.23 USD +4.50% vs prior close
Relmada Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Market cap
557.5M USD
EPS, diluted, year to Dec 2025
−1.45 USD
52-week range
0.563 USD – 7.88 USD
Avg volume
526.2K

as of Jul 17, 2026

Have Relmada Therapeutics (RLMD) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Relmada Therapeutics insiders reported 4 open-market purchases and no sales (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 10 Sep 2026

4buys
0sells
$1.67Mnet bought
0other filings
Have Relmada Therapeutics (RLMD) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Sep 2026Shenouda MagedChief Financial OfficerBuy79,800339K USD
10 Sep 2026TRAVERSA SERGIOChief Executive OfficerBuy100,000410K USD
09 Sep 2026Shenouda MagedChief Financial OfficerBuy120,200505K USD
09 Sep 2026TRAVERSA SERGIOChief Executive OfficerBuy100,000418K USD
Bought4 open-market purchases400,000$1.67M

Which funds hold Relmada Therapeutics (RLMD)?

8 of the 45 institutional funds we track reported a Relmada Therapeutics position for the quarter ended 30 Sep 2026 — a combined 26.6M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Relmada Therapeutics (RLMD)?
FundPositionSharesValueShares q/q
Millennium ManagementAdded3,345,57312.6M USD+41.7%
Balyasny Asset ManagementHeld (±25%)1,503,7605.7M USD−1.1%
Marshall WaceTrimmed603,3572.3M USD−73.1%
Renaissance TechnologiesAdded503,1921.9M USD+770.6%
Citadel AdvisorsTrimmed442,1031.7M USD−58.4%
D. E. Shaw & Co.Added418,3871.6M USD+282.2%
Two Sigma InvestmentsTrimmed158,932599K USD−26.0%
AQR Capital ManagementNew position74,490281K USD

Have members of Congress traded Relmada Therapeutics (RLMD)?

The most recent congressional trade disclosed in Relmada Therapeutics is a sale by Sara Jacobs (house, CA), dated 12 Dec 2022.

STOCK Act disclosures

Have members of Congress traded Relmada Therapeutics (RLMD)?
TradedMemberTypeAmountFiled after
12 Dec 2022Sara Jacobshouse · Democrat–CASale1K USD–15K USD39 days
08 Nov 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD34 days

What has been filed or recorded for Relmada Therapeutics (RLMD)?

The filings we hold for Relmada Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 20 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Relmada Therapeutics (RLMD)?
And
20 Oct 2026Fails to deliverShares failed to deliver327,973 shares1.0M USD notional · 0.307% of shares out
19 Oct 2026Fails to deliverShares failed to deliver328,085 shares1.0M USD notional · 0.307% of shares out
16 Oct 2026Fails to deliverShares failed to deliver228,185 shares730K USD notional · 0.214% of shares out
15 Oct 2026Fails to deliverShares failed to deliver128,421 shares416K USD notional · 0.120% of shares out
09 Oct 2026Fails to deliverShares failed to deliver300,758 shares953K USD notional · 0.282% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.12 USD
30 Sep 2026FinancialsTotal assets205.3M USDat period end
30 Sep 2026FinancialsTotal equity193.7M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.11 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.22 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.45 USD
31 Dec 2025FinancialsNet income−57.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.45 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.30 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.30 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.58 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −2.65 USD

What do people ask about Relmada Therapeutics (RLMD)?

From live data
What is Relmada Therapeutics’ market cap?557.5M

Relmada Therapeutics is worth 557.5M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Relmada Therapeutics insiders bought or sold shares recently?4 purchases

In the 90 days to 22 Nov 2026, Relmada Therapeutics insiders reported 4 open-market purchases and no sales (SEC Form 4). See Insiders

Which funds own Relmada Therapeutics?8 of 45

8 of the 45 funds we track reported a Relmada Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Balyasny Asset Management and Marshall Wace. See Funds

Have members of Congress traded Relmada Therapeutics?2 trades

Yes. 2 trades in Relmada Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Relmada Therapeutics last report earnings?−0.12

Relmada Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.12 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings
  11. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words